Advances in Multi-Omics of Pediatric, Adolescence and Young Adult Cancers

Dear Colleagues,

Pediatric and adolescent and young adult (AYA) cancers are relatively uncommon but remain one of the leading causes of death in these age groups. Despite recent advances in multimodal cancer treatment, a significant proportion of pediatric and AYA cancer patients continue to experience poor outcomes. Omics technologies, including (but not limited to) genomics, transcriptomics, proteomics, and metabolomics, offer a comprehensive approach via which to better understand pediatric and AYA cancers. The integration of Omics data at multiple levels (multi-Omics) can provide a complete picture of the genetic and molecular alterations responsible for the poor outcomes observed in pediatric and AYA cancers, as well as identify novel therapeutic targets and discover molecular biomarkers that enable precise diagnosis and treatment.

This Special Issue aims to collect new evidence and perspectives from researchers who work at the interface between Omics technologies and pediatric and AYA cancers. Original research articles, short communications, and reviews (including systematic review and meta-analysis) are most welcome. Clinical case report/series that apply Omics in order to support clinical decision making regarding the diagnosis or treatment selection will also be considered for peer-review.

Research areas may include (but are not limited to) the following:

• Omics as part of cancer biology, biomarker, and clinical studies in pediatric and AYA cancer
• Updates in cancer predisposition genes and syndromes;
• Cutting-edge Omics technologies applied to obtain new insights in pediatric and AYA cancers, e.g., single-cell Omics, spatial Omics, PTM (phospho-, ubiquitin-, glyco-) proteomics;
• Extracellular vesicle (EV)-derived Omics in pediatric and AYA cancers;
• Molecular epidemiology and exposomics in pediatric and AYA cancers;
• Bioinformatic methods and tools, and new databases that facilitate Omics applications in pediatric and AYA cancers;
• Cost analysis of Omics-based clinical investigations;
• Validation study of Omics findings obtained from publicly available databases or previous publications using conventional methods and clinically compatible assays.

We look forward to receiving your contributions.

Dr. Somchai Chutipongtanate
Dr. Surasak Sangkhathat
Dr. Dumnoensun Pruksakorn
Dr. Valli De Re
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.